Systemic elastin degradation in chronic obstructive pulmonary disease

Thorax

Volumn 67, Issue 7, 2012, Pages 606-612

  Maclay, John D ^a   McAllister, David A ^a   Rabinovich, Roberto ^a   Haq, Imran ^b   Maxwell, Scott ^c   Hartland, Stephen ^a   Connell, Martin ^a,c   Murchison, John T ^c   Van Beek, Edwin J R ^a   Gray, Robert D ^a   Mills, Nicholas L ^d   MacNee, William ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; ELASTIN; GELATINASE A; GELATINASE B; MACROPHAGE ELASTASE; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGED; ARTERIAL STIFFNESS; ARTERY BLOOD FLOW; ARTICLE; CAROTID ARTERY PULSE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; EMPHYSEMA; FEMORAL ARTERY PULSE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PULSE WAVE; QUANTITATIVE ANALYSIS; SKIN BIOPSY; SMOKING CESSATION; SUN EXPOSURE; WRINKLE; ZYMOGRAPHY;

EID: 84862771218     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2011-200949     Document Type: Article

References (51)

1. Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001;163:1256-76.
2. Celli BR, MacNee W, Agusti A, et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-46.
3. Maclay JD, McAllister DA, Mills NL, et al. Vascular dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;180:513-20.
4. Sabit R, Bolton CE, Edwards PH, et al. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:1259-65.
5. Eickhoff P, Valipour A, Kiss D, et al. Determinants of systemic vascular function in patients with stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;178:1211-18.
6. McAllister DA, Maclay JD, Mills NL, et al. Arterial stiffness is independently associated with emphysema severity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;176:1208-14.
7. Shifren A, Mecham RP. The stumbling block in lung repair of emphysema: elastic fiber assembly. Proc Am Thorac Soc 2006;3:428-33.
8. Turino GM. Proteases in COPD: a critical pathway to injury. Chest 2007;132:1724-5.
9. Hunninghake GM, Cho MH, Tesfaigzi Y, et al. MMP12, lung function, and COPD in high-risk populations. N Engl J Med 2009;361:2599-608.
10. Atkinson JJ, Lutey BA, Suzuki Y, et al. The role of matrix metalloproteinase (MMP)-9 in cigarette smoke-Induced emphysema. Am J Respir Crit Care Med 2011:876-84.
11. Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol 2005;25:932-43.
12. Labella F, Lindsay WG. The structure of human aortic elastin as influenced by age. J Gerontol 1963;18:111-18.
13. Smith BS, Williamson N, McConkey B. Dermal connective tissue in patients with chronic obstructive airways disease. Lancet 1967;1:341-3.
14. Lee S-H, Goswami S, Grudo A, et al. Antielastin autoimmunity in tobacco smoking-induced emphysema. Nat Med 2007;13:567-9.
15. Patel BD, Loo WJ, Tasker AD, et al. Smoking related COPD and facial wrinkling: is there a common susceptibility? Thorax 2006;61:568-671.
16. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005;26:319-38.
17. Robert C, Lesty C, Robert AM. Ageing of the skin: study of elastic fiber network modifications by computerized image analysis. Gerontology 1988;34:291-6.
18. Francès C, Boisnic S, Hartmann DJ, et al. Changes in the elastic tissue of the non-sun- exposed skin of cigarette smokers. Br J Dermatol 1991;125:43-7.
19. Just M, Ribera M, Monsó E, et al. Effect of smoking on skin elastic fibres: morphometric and immunohistochemical analysis. Br J Dermatol 2007;156:85-91.
20. Gilchrest BA. Skin aging and photoaging: an overview. J Am Acad Dermatol 1989;21:610-13.
21. ImageJ User Guide. National Institute of Health, 2011. http://rsbweb.nih.gov/ij/docs/ guide/userguide.html (accessed 19 Feb 2011).
22. Stoel BC, Connell M. Quantitative analysis of emphysema in 3D using MDCT: correction of air offset in Toshiba scanners. Eur J Radiol 2008;65:235-6.
23. Mair G, Miller JJ, McAllister DA, et al. Computed tomographic emphysema distribution: relationship to clinical features in a cohort of smokers. Eur Respir J 2009;33:536-42.
24. Laurent S, Cockcroft J, Van Bortel L, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006;27:2588-605.
25. Bolton CE, Mceniery CM, Raj V, et al. Aortic calcification, arterial stiffness and bone mineral density in patients with COPD. Artery Res 2011;5:30-6.
26. Dransfield MT, Huang F, Nath H, et al. CT emphysema predicts thoracic aortic calcification in smokers with and without COPD. COPD 2010;7:404-10.
27. McAllister DA, MacNee W, Duprez D, et al. Pulmonary function is associated with distal aortic calcium not proximal aortic distensibility: MESA Lung Study. COPD 2011;8:71-8.
28. Atkinson J. Age-related medial elastocalcinosis in arteries: mechanisms, animal models, and physiological consequences. J Appl Physiol 2008;105:1643-51.
29. Riley DJ, Thakker-Varia S. Effect of diet on lung structure, connective tissue metabolism and gene expression. J Nutr 1995;125:1657Se60.
30. Just M, Monsó E, Ribera M, et al. Relationships between lung function, smoking and morphology of dermal elastic fibres. Exp Dermatol 2005;14:744-51.
31. Baraldo S, Bazzan E, Zanin ME, et al. Matrix metalloproteinase-2 protein in lung periphery is related to COPD progression. Chest 2007;132:1733-40.
32. Chung AW, Yang HH, Kim JM, et al. Upregulation of matrix metalloproteinase-2 in the arterial vasculature contributes to stiffening and vasomotor dysfunction in patients with chronic kidney disease. Circulation 2009;120:792-801.
33. Yasmin, McEniery CM, Wallace S. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol 2005;25:372-8.
34. Yasmin, McEniery CM, O'Shaughnessy KM, et al. Variation in the human matrix metalloproteinase-9 gene is associated with arterial stiffness in healthy individuals. Arterioscler Thromb Vasc Biol 2006;26:1799-805.
35. Aldonyte R, Jansson L, Piitulainen E, et al. Circulating monocytes from healthy individuals and COPD patients. Respir Res 2003;4:11.
36. Agustí A, Macnee W, Donaldson K, et al. Hypothesis: does COPD have an autoimmune component? Thorax 2003;58:832-4.
37. Chakrabarti S, Patel KD. Regulation of matrix metalloproteinase-9 release from IL-8- stimulated human neutrophils. J Leukoc Biol 2005;78:279-88.
38. Chakrabarti S, Zee JM, Patel KD. Regulation of matrix metalloproteinase-9 (MMP- 9) in TNF-stimulated neutrophils: novel pathways for tertiary granule release. J Leukoc Biol 2006;79:214-22.
39. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003;92:827-39.
40. Luan Z. Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol 2003;23:769-75.
41. Kamio K, Liu XD, Sugiura H, et al. Statins inhibit matrix metalloproteinase release from human lung fibroblasts. Eur Respir J 2010;35:637-46.
42. Bellosta S, Via D, Canavesi M, et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 1998;18:1671-8.
43. Underwood DC, Osborn RR, Bochnowicz S, et al. SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am J Physiol Lung Cell Mol Physiol 2000;279:L895-902.
44. Fisher GJ, Wang ZQ, Datta SC, et al. Pathophysiology of premature skin aging induced by ultraviolet light. N Engl J Med 1997;337:1419-28.
45. Henriksen PA, Sallenave J-M. Human neutrophil elastase: mediator and therapeutic target in atherosclerosis. Int J Biochem Cell Biol 2008;40:1095-100.
46. Stockley RA. Neutrophils and the pathogenesis of COPD. Chest 2002;121:151Se5.
47. Lutgens E, Lutgens SPM, Faber BCG, et al. Disruption of the cathepsin K gene reduces atherosclerosis progression and induces plaque fibrosis but accelerates macrophage foam cell formation. Circulation 2006;113:98-107.
48. Golovatch P, Mercer BA, Lemaître V, et al. Role for Cathepsin K in emphysema in smoke-exposed guinea pigs. Exp Lung Res 2009;35:631-45.
49. Deslee G, Woods JC, Moore CM, et al. Elastin expression in very severe human COPD. Eur Respir J 2009;34:324-31.
50. Autio P, Karjalainen J, Risteli L, et al. Effects of an inhaled steroid (budesonide) on skin collagen synthesis of asthma patients in vivo. Am J Respir Crit Care Med 1996;153:1172-5.
51. Haapasaari K, Rossi O, Risteli J, et al. Effects of long-term inhaled corticosteroids on skin collagen synthesis and thickness in asthmatic patients. Eur Respir J 1998;11:139-43.